FDA removes longtime over-the-counter drugs regulator

The move comes one day after CDER Director Richard Pazdur announced his retirement.

December 3, 2025 Check out STAT+

Sponsored By

For the past two decades, many of the biggest advances in medicine have arrived first in diseases of the blood. For our Orlando-area readers, join STAT's award-winning journalists, some of the top experts in the field, and executives from leading companies for a look at what is coming next at an event this Friday evening. More details here.

Jacquelyn Martin/AP STAT+ | FDA removes longtime over-the-counter drugs regulator from her position The move comes a day after Richard Pazdur, a top FDA official and Michele's boss, announced his decision to retire. By Lizzy Lawrence As vaccine panel prepares hepatitis B review, CDC and industry experts are excluded CDC and manufacturer experts not consulted in ACIP review, raising concerns over transparency, science, and the future of the hepatitis B vaccine schedule. By Daniel Payne and Chelsea Cirruzzo Opinion: CDC's vaccine advisory panel faces a crisis of its own making ACIP's upcoming meeting on hepatitis B vaccine birth dose and other policy questions is worrying experts. By Demetre Daskalakis, Daniel Jernigan, and Debra Houry Adobe STAT+ | AI scribes may not save a lot of time on clinical notes, but they make clinicians happy As health systems study the impact of ambient scribes, they are finding that clinicians love the tools, even though they don't seem to save that much time. By Mario Aguilar and Brittany Trang STAT+ | Aging startup backed by Sam Altman chases $5 billion valuation The longevity startup backed by OpenAI CEO Sam Altman is close to raising what could be one of the drug industry's largest investment rounds By Allison DeAngelis Former CDC official returns to local health care after resigning Former CDC official Demetre Daskalakis says that ideology is overruling science at federal agencies, explains why he's returning to local work. By Theresa Gaffney Opinion: 'Where's our CRISPR miracle?' "There was a clear gap in communication" between parents of children with rare diseases and the scientists behind a major recent CRISPR breakthrough. By Torie Bosch STAT+ | Hair loss drug succeeds in Phase 3, but data underwhelms experts The topical medication treats a common form of hair loss called androgenetic alopecia. By Allison DeAngelis STAT+ | Capricor says its cell therapy improved heart and muscle function in Duchenne patients The outcome in the latest Phase 3 study will likely bolster the treatment's regulatory future with the Food and Drug Administration. By Adam Feuerstein and Jason Mast

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Daily Recap? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser